Global Probiotic IBS Supplements Market - 2024-2031

Global Probiotic IBS Supplements Market - 2024-2031


Global Probiotic IBS Supplements Market reached US$ 29.12 million in 2023 and is expected to reach US$ 48.79 million by 2031, growing with a CAGR of 7.65% during the forecast period 2024-2031.

Probiotics have shown a potential to relieve irritable bowel syndrome symptoms. An American College of Gastroenterology meta-analysis found that probiotics may help improve overall IBS symptoms, including bloating and flatulence. The expansion of the probiotics market is propelled by heightened consumer awareness of the benefits to gut health, a growing incidence of digestive disorders, and continuous exploration of probiotics' potential health impacts extending beyond digestion.

There's a heightened awareness among consumers regarding the potential benefits of probiotics for digestive health, including managing symptoms of IBS. As more people become familiar with probiotics and their role in promoting gut health, the demand for probiotic supplements, specifically related to conditions like IBS, increases driving the market growth worldwide.

North America dominates the global probiotic IBS supplements market. The high use of probiotic supplements in various aspects of application in North America is positively improving the market expansion in this region. According to the Food and Health Survey conducted by the International Food Information Council in April 2022, around 33% of respondents in the United States make an effort to include probiotics in their diets, with 60% aiming to do so daily.

Dynamics

Increasing Prevalence of Irritable Bowel Syndrome

The rising incidence of IBS worldwide is a significant driver for the probiotic supplements market. According to the International Foundation for Gastrointestinal Disorders, the worldwide estimation of IBS is reported to be 5-10% of the population. Similarly, in September 2023, results from a new study by Cedars-Sinai investigators revealed that irritable bowel syndrome is more prevalent than previously thought. Approximately 20 to 40% of all visits to gastroenterologists are due to IBS symptoms.

As more individuals are diagnosed with IBS, there's a growing demand for effective management and relief options, with probiotics being one of the preferred choices due to their perceived benefits in gut health. Many individuals prefer natural and holistic approaches to managing health conditions like IBS. Probiotics, which consist of beneficial bacteria that promote a healthy gut microbiota, align well with this preference for natural remedies.

Rising Use of Probiotics

Probiotics are known for their potential to promote digestive health by maintaining a balanced intestinal microbiota and supporting immune function. Increasing consumer awareness regarding the benefits of probiotics is driving the wide consumption of probiotics in various application sectors including digestive health.

In a 2021 survey conducted by the International Food Information Council, findings indicated that 51% of Americans incorporate probiotics into their diets to promote gut health, 33% use them to bolster immune function, 38% integrate probiotics for overall health and wellness purposes, and 13% reported consuming probiotics to support emotional well-being.

Probiotics are believed to help restore the balance of gut bacteria, which can be disrupted in individuals with IBS. Some studies suggest that certain probiotic strains may help relieve IBS symptoms by modulating gut microbiota composition, reducing inflammation and improving intestinal barrier function. According to NIH, numerous meta-analyses have evaluated the impact of probiotics on individuals with IBS with the majority concluding that probiotics offer a positive effect in alleviating symptoms.

Competition from Pharmaceutical Treatments

While probiotic supplements offer a natural and holistic approach to managing IBS symptoms, they face competition from pharmaceutical treatments. The treatments such as antispasmodics, laxatives and antidepressants, are commonly prescribed for IBS management. Pharmaceutical treatments offer a different approach to symptom management compared to probiotic supplements.

Pharmaceutical treatments typically target specific symptoms or underlying mechanisms of the condition. They provide more immediate relief of symptoms such as abdominal pain, bloating, and irregular bowel movements. In addition, they are often prescribed by healthcare professionals, providing a level of assurance and guidance for patients seeking symptom relief.

Segment Analysis

The global probiotic IBS supplements market is segmented based on strain, form, distribution channel, end-user and region.

Potential Benefits of Bifidobacterium

The global probiotic IBS supplements market is segmented based on strain into lactobacillus, bifidobacterium and others. The bifidobacterium segment accounted for the largest share of the global market. Bifidobacterium strains, such as Bifidobacterium infantis and Bifidobacterium longum, have been extensively studied for their potential benefits in managing symptoms of IBS.

Clinical trials and research studies have consistently shown positive outcomes, including improved abdominal pain, bloating and bowel habits. According to Harvard studies, Bifidobacterium bifidum MIMBb75, probiotic strain, has demonstrated strong adherence to intestinal cells, suggesting it may effectively modify the gut microbiota and enhance the intestinal barrier.

Clinical trials published in Alimentary Pharmacology & Therapeutics have shown that daily supplementation with Bifidobacterium bifidum MIMBb75 significantly improved overall IBS symptoms, as well as individual symptoms like abdominal pain, bloating and fecal urgency. Also, recent research has indicated that even heat-inactivated Bifidobacterium bifidum MIMBb75 can relieve IBS symptoms.

Geographical Penetration

High Prevalence of Irritable Bowel Syndrome in North America

North America dominates the global probiotic IBS supplements market. North America has a relatively high prevalence of irritable bowel syndrome, with millions of individuals affected by this condition. The International Foundation for Gastrointestinal Disorders recently reported that IBS affects between 25 and 45 million people in United States. About 2 in 3 IBS sufferers are female, while 1 in 3 IBS sufferers are male.

The large patient population creates a significant market opportunity for products targeting IBS management. With a strong culture of health and wellness in North America, many consumers actively seek natural and holistic approaches to managing health conditions like IBS. Probiotic supplements are perceived as safe and effective options for promoting digestive health and alleviating symptoms of IBS, fitting well with the preferences of health-conscious consumers in the region.

Competitive Landscape

The major global players in the market include The Good Bug, Zeroharm Sciences Private Limited, Menoveda Life Sciences Private Limited, Unique Biotech Limited, Projoy Pvt Ltd, Pure NSM - Nutritional Supplement Manufacturers, Inc., Nature's Bounty, Hyperbiotics, Advanced Vital Enzymes Private Ltd and Wren Laboratories Ltd.

COVID-19 Impact Analysis

The COVID-19 had a moderate impact on the global probiotic IBS supplements market. The probiotic supplements market, like many other industries, has been impacted by disruptions in global supply chains caused by the pandemic. Restrictions on travel, closures of manufacturing facilities and logistical challenges have led to delays in production and distribution, affecting the availability of probiotic products in some regions.

The pandemic has heightened awareness about the importance of maintaining a healthy immune system. Probiotics, known for their role in gut health, have gained attention for their potential immune-supporting properties. The greater demand for products perceived to promote overall health positively impacted the probiotic supplements market. Individuals with IBS are motivated to explore natural remedies like probiotics to support their immune and digestive health.

By Strain
• Lactobacillus
• Bifidobacterium
• Other

By Form
• Tablet
• Capsules
• Liquid
• Powder
• Others

By Distribution Channel
• Supermarkets/Hypermarkets
• Pharmacy/Health Stores
• Online Stores
• Other

By End-User
• Infant
• Children
• Adults
• Seniors

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Russia
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In August 2023, Hyperbiotics introduced PRO-IBS Support. This innovative product features a dual-action synergistic blend of Lactiplantibacillus plantarum 299v and highly bioavailable Boswellia serrata extract. The formulation aims to effectively alleviate gut discomfort and dysfunction in individuals with IBS.
• In August 2022, researchers at the University of Nottingham secured £1.8 million in funding for a three-year project to explore the potential benefits of cellulose-based food supplements for individuals suffering from Irritable Bowel Syndrome, focusing on colon fermentation.

Why Purchase the Report?
• To visualize the global probiotic IBS supplements market segmentation based on strain, form, distribution channel, end-user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of probiotic IBS supplements market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global probiotic IBS supplements market report would provide approximately 70 tables, 76 figures and 235 pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies


1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Strain
3.2. Snippet by Form
3.3. Snippet by Distribution Channel
3.4. Snippet by End-User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Irritable Bowel Syndrome
4.1.1.2. Rising Use of Probiotics
4.1.2. Restraints
4.1.2.1. Competition from Pharmaceutical Treatments
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Strain
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
7.1.2. Market Attractiveness Index, By Strain
7.2. Lactobacillus
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bifidobacterium
7.4. Other
8. By Form
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
8.1.2. Market Attractiveness Index, By Form
8.2. Tablet
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Capsules
8.4. Liquid
8.5. Powder
8.6. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Supermarkets/Hypermarkets
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Pharmacy/Health Stores
9.4. Online Stores
9.5. Other
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Infants
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Children
10.4. Adults
10.5. Seniors
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strain
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. The Good Bug
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Zeroharm Sciences Private Limited
13.3. Menoveda Life Sciences Private Limited
13.4. Unique Biotech Limited
13.5. Projoy Pvt Ltd
13.6. Pure NSM - Nutritional Supplement Manufacturers, Inc.
13.7. Nature's Bounty
13.8. Hyperbiotics
13.9. Advanced Vital Enzymes Private Ltd
13.10. Wren Laboratories Ltd
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings